Press Releases

CRANBURY, NJ, Sept. 6, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN; “Palatin”) announced today that it has entered into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”), for exclusive rights to develop and commercialize bremelanotide for female sexual […]

May 16, 2017, 07:30 ET CRANBURY, N.J., May 16, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2017.  Quarter and Recent Highlights Bremelanotide –

May 11, 2017, 07:30 ET CRANBURY, N.J., May 11, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2017 operating results on Tuesday, May 16, 2017  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

CRANBURY, N.J., March 20, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial

Mar 09, 2017, 15:00 ET CRANBURY, N.J., March 9, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that it will be presenting at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 11:00 a.m. Pacific Time.  The conference will be held at The Ritz Carlton Laguna Niguel in Dana Point, CA.

CRANBURY, N.J., Feb. 9, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2016.  Recent Highlights Rekynda (bremelanotide) – Under development for Hypoactive Sexual Desire

Will Also Report Second Quarter 2017 Results and Discuss Next Steps in its Development Programs Teleconference and Webcast to be held on February 9, 2017 Feb 03, 2017, 06:00 ET CRANBURY, N.J., Feb. 3, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced the closing of its license agreement with AMAG Pharmaceuticals, Inc. (Nasdaq:

CRANBURY, N.J., Jan. 10, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that after the closing of its licensing agreement with AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) for exclusive North American rights to develop and commercialize Rekynda™ (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, it

CRANBURY, N.J., Dec. 7, 2016 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE MKT: PTN) announced that it has closed on a previously disclosed underwritten public offering of units with gross proceeds of $16,500,000.  Canaccord Genuity acted as sole book-running manager, Roth Capital Partners acted as lead manager and Chardan Capital Markets acted as co-manager for the

Dec 01, 2016, 08:20 ET CRANBURY, N.J., Dec. 1, 2016 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE MKT: PTN) today announced the pricing of an underwritten public offering of 25,384,616 shares of its common stock and warrants to purchase 12,692,310 shares of its common stock for anticipated gross proceeds of $16.5 million, before deducting underwriting discounts